Isatuximab in multiple myeloma

References

• Abramson HN. Immunotherapy of multiple myeloma: promise and challenges. 2021;Volume 10(10):343–371.
   Google Scholar
• Zhu C, Song Z, Wang A, et al. Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells. Front Immunol. 2020 14;11: 1771. . 10.3389/fimmu.2020.01771
   PubMed Web of Science ®Google Scholar
• Martin T, Strickland S, Glenn M, et al. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. Blood Cancer J. 2019 29; 9(4): 41. 10.1038/s41408-019-0198-4.
   PubMed Web of Science ®Google Scholar
• Mikhael J, Richter J, Vij R, et al. A dose-finding phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia. 2020;34(12):3298–3309. DOI:10.1038/s41375-020-0857-2
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Bringhen S, Anttila P, et al. Results from a phase II study of isatuximab as a single agent and in combination with dexamethasone in patients with relapsed/refractory multiple myeloma. Blood. 2018;132(suppl 1):155. DOI:10.1182/blood-2018-155
   Google Scholar
• Richardson PG, Perrot A, San-Miguel J, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 Mar;23(3):416–427.
   PubMed Web of Science ®Google Scholar
• Mikhael J, Richardson P, Usmani SZ, et al. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 2019;134(2):123–133. DOI:10.1182/blood-2019-02-895193
   PubMed Web of Science ®Google Scholar
• Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096–2107. DOI:10.1016/S0140-6736(19)32556-5
   PubMed Web of Science ®Google Scholar
• Schjesvold F, Richardson PG, Facon T, et al. Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: iCARIA-MM subgroup analysis. Haematologica. 2022 Mar 1;107(3):774–775. DOI:10.3324/haematol.2021.279160
   PubMed Web of Science ®Google Scholar
• Harrison SJ, Perrot A, Alegre A, et al. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. Br J Haematol. 2021 Jul;194(1):120–131.
   PubMed Web of Science ®Google Scholar
• Hulin C, Beksac M, Goodman HJ, et al. Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma. Blood Cancer J. 11(10). 169. 2021 Oct 20. 10.1038/s41408-021-00562-9.
   PubMed Web of Science ®Google Scholar
• Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;129(25):3294–3303. DOI:10.1182/blood-2016-09-740787
   PubMed Web of Science ®Google Scholar
• Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet. 2021;397(10292):2361–2371. DOI:10.1016/S0140-6736(21)00592-4
   PubMed Web of Science ®Google Scholar
• Spicka I, Moreau P, Martin TG, et al. Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: iKEMA subgroup analysis. Eur J Haematol. 2022;109(5):504–512.
   PubMed Web of Science ®Google Scholar
• Martin T, Mikhael J, Hajek R, et al. Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma: ikema interim analysis. Blood. 2020;136(suppl 1):7–8. DOI:10.1182/blood-2020-137681
   Google Scholar
• Ocio E, Otero PR, Bringhen S, et al. Preliminary results from a phase I study of isatuximab (ISA) in combination with bortezomib, lenalidomide, dexamethasone (VRd), and in patients with newly diagnosed multiple myeloma (NDMM) non-eligible for transplant. Blood. 2018;132(suppl 1):3160. DOI:10.1182/blood-2018-99-111244
   Google Scholar
• Ocio EM, Bringhen S, Oliva S, et al. A phase Ib study of isatuximab in combination with bortezomib, cyclophosphamide, and dexamethasone (VCDI) in patients with newly diagnosed multiple myeloma non-eligible for transplantation. Blood. 2017;130(suppl 1):3160.
   Google Scholar
• Ocio EM, Rodríguez Otero P, Bringhen S, et al. Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM). J Clin Oncol. 2020;38(suppl 15):8529. DOI:10.1200/JCO.2020.38.15_suppl.8529
   Web of Science ®Google Scholar
• Goldschmidt H, Mai EK, Nievergali E, et al. Addition of isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG-HD7 trial. Blood. 2021;138(suppl 1):463.
   Google Scholar
• Leypoldt LB, Besemer B, Asemissen AM, et al. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in frontline treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia. 2022;36(3):885–888.
   PubMed Web of Science ®Google Scholar
• Facon T, Moreau P, Baker R, et al. Isatuximab plus carfilzomib and dexamethasone in patients with early versus late relapsed multiple Myeloma: ikema subgroup analysis. Blood. 2022;140(Supplement 1):1820–1822. DOI:10.1182/blood-2022-159105
   Google Scholar
• Quach H, Parmar G, Ocio EM, et al. Subcutaneous Isatuximab administration by an on-body delivery system (OBDS) in combination with Pomalidomide and Dexamethasone in patients with relapsed/refractory multiple Myeloma: phase 1b expansion study results blood. 2022;140(Supplement 1):4412–4414. DOI:10.1182/blood-2022-166840.
   Google Scholar
• O’donnell EK, Mo CC, Nadeem O, et al. A Phase II study of once weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in newly diagnosed, transplant-eligible multiple Myeloma (The SKylaRk Trial). Blood. 2022;140(Supplement 1):7282–7283. DOI:10.1182/blood-2022-156328
   Google Scholar
• Verkleij CPM, Jhatakia A, Broekmans MEC, et al. Preclinical rationale for targeting the PD-1/PD-L1 axis in combination with a CD38 antibody in multiple myeloma and other CD38-positive malignancies. Cancers (Basel). 2020;12(12):3713. DOI:10.3390/cancers12123713
   PubMed Web of Science ®Google Scholar